Ovid Therapeutics Inc.OVID

時価総額

$9528.7万

PER

脳疾患治療薬の新興企業。薬剤開発を展開。2021年12月のアストラゼネカ契約で$5.0M前払と最大$203Mのマイルストーン、2022年8月のGensaicへ$5.1M出資。米国拠点、米欧中心の展開。

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-64,806,054	-51,979,610	-60,461,243	-81,035,576	123	-54,169,029	-52,338,959	-26
Change in fair value of royalty monetization liability	-	-	-	-	-	-	-	-30
Unrealized (gain) loss on equity investments	-	-	-	-	-	-454,811	2	3
Change In Accrued Interest And Accretion Of Discounts Short Term Investments	-	-	-	-	-	-	-2,172,254	-3
Stock-based compensation expense	6	7	5	8	5	7	7	6
Depreciation and amortization expense	80,310	141,733	255,002	306,848	237,079	512,505	568,282	1
Noncash operating lease expense	-	-	-	-	-	869,100	1	1
Change in lease liability	-	-	-	-	-	-	-533,946	-1
Prepaid expenses and other current assets	793,258	1	-224,458	724,575	-14,089	-109,292	1	-1
Accounts payable	1	2	-653,953	2	2	-5,174,136	2	-1
Accrued expenses	1	1	2	5	-4,361,410	-3,166,606	2	-1
Net cash used in operating activities	-	-45,558,480	-51,090,622	-51,583,914	119	-55	-46	-56
Purchase of marketable securities	-	50	35	10	-	173	112	73
Sales/maturities of marketable securities	-	-	-	-	-	90	120	128
Purchase of long-term equity investment	-	-	-	-	-	3	10	-
Purchases of property and equipment	38,907	33,871	57,156	127,240	184,008	1	40,308	0
Software development and other costs	-	-	186,889	263,440	5,400	194,397	97,147	0
Net cash provided by (used in) investing activities	-	-5,363,642	-30,041,049	35	-1,821,400	-87,883,217	-2,580,605	55
Proceeds from Stock Options Exercised	27,043	111,378	-	300,821	807,191	180,658	535,201	1
Proceeds from royalty monetization agreement	-	-	-	-	-	-	30	-
Net cash provided by financing activities	-	286,140	87	47	904,082	180,658	31	1
Net decrease in cash, cash equivalents and restricted cash	-	-	-	-	-	-	-17,826,329	-1